Olon has a long-standing reputation in API manufacturing, but what drives the company beyond simply producing APIs?
At Olon, our mission goes far beyond manufacturing APIs. We are driven by the belief that our work should make tomorrow’s medicines safer, more sustainable, and more accessible for patients worldwide.
As a global company with a long history of excellence, we see our responsibility not only in meeting today’s needs but also in anticipating the challenges ahead. By combining innovation with responsibility, we set new benchmarks for quality, safety, and environmental stewardship.
Our new High Potency API suite is a clear expression of this vision. More than just a facility, it represents a gateway to new possibilities. Precision medicine and niche therapies are reshaping the pharmaceutical landscape, and we are proud to be among the very few API suppliers able to offer a fully integrated portfolio of solutions. From chemically synthesized compounds to semisynthetic APIs and complex biologics, our capabilities span the full spectrum.
What strategic role does the new Rodano facility play in strengthening Olon’s position as a global CDMO for high-potency APIs?
The Rodano facility is a cornerstone of our growth strategy. It reinforces Olon’s role as a global CDMO for high-potency APIs by expanding our capabilities across the entire development and manufacturing lifecycle. It positions us as a partner of choice for companies that seek innovation, reliability, and speed to market.
At the same time, we view HPAPI and bioconjugation as deeply interconnected fields. Many next-generation therapies – such as antibody-drug conjugates (ADCs) and other complex bioconjugates – rely on ultra-potent payloads. This is where Olon stands out: we combine decades of HPAPI expertise with new capabilities in bioconjugation, following our acquisition of GTP Bioways in 2024.
The synergy between our advanced HPAPI platform and our expanding bioconjugation offering makes Olon one of the few CDMOs able to provide integrated solutions across the entire bioconjugates spectrum. This means we can support clients with both the payload development and the conjugation technologies required to bring next-generation targeted therapies to market.
Looking ahead, we are investing in the expansion of both areas, Rodano’s OEB6 capacity for ultra-potent payloads and our dedicated bioconjugation facilities, so that together, they form a global platform enabling speed, innovation, and reliability for our partners.
Olon has invested in containment over the past five years. How does this investment translate into tangible benefits for your clients?
Our mission is to invest today in capabilities that will build a more sustainable, innovative, and accessible healthcare ecosystem tomorrow.
Over the past five years, we have invested more than €40 million to strengthen our capabilities. These investments extend far beyond infrastructure upgrades. A prime example is our sustainable fermentation platform, which represents a major step forward in the manufacturing of semi-synthetic HPAPIs with a reduced environmental footprint. This innovation has been recognized with the prestigious 2025 CMO Excellence in Green Chemistry Award, conferred by the ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR). The award highlights our pioneering work in the sustainable production of therapeutic peptides, achieved through recombinant DNA (rDNA) technology and chimeric protein expression in microbial fermentation.
Looking ahead, our investments are expanding capabilities not only in high-potency APIs but also in complex conjugated modalities, ranging from ADC payloads to other biologic conjugates and therapies for rare diseases. For our clients, this translates directly into faster timelines, flexible production volumes, and reliable delivery of some of the most challenging and innovative molecules in today’s pipeline.
How does Olon collaborate with in today’s increasingly complex pharmaceutical landscape?
Collaboration is at the very heart of our identity. The pharmaceutical landscape is becoming more complex every day, shaped by evolving regulations, the rapid pace of innovation, and the need for agility. In such an environment, no company can succeed in isolation. That is why we put our clients at the center of everything we do. We take a flexible and adaptive approach, tailoring solutions to each partner’s specific needs, whether that means refining processes, scaling production rapidly, or integrating the latest technologies.
Quality, of course, is non-negotiable. We have built robust quality systems and a culture of continuous improvement to ensure that every project we deliver meets the highest standards. Just as importantly, we build partnerships on transparency and trust. By working side by side from early development to commercial manufacturing, we create shared goals and shared success.
Looking ahead, what is in the future
Olon is committed to continuing its growth across the full spectrum of healthcare, focusing particularly on areas of high scientific complexity and therapeutic impact. We see sustained growth in high-potency therapeutics, driven by oncology, rare diseases, and immune-modulating therapies. To serve this demand, we will keep investing in next-generation containment, advanced manufacturing technologies, and sustainable practices that minimize environmental impact.
By combining innovation with operational excellence, Olon is not simply adapting to the pharmaceutical industry’s evolution, we are helping to shape its future.
What role does sustainability and responsibility play in Olon’s strategy?
Sustainability and responsibility are integral to everything we do. We are committed to reducing our environmental footprint without compromising quality or safety. Across our operations, we embed sustainable practices, from energy-efficient facilities to greener technologies, to waste reduction strategies.
Ultimately, sustainability for us is not only about compliance or efficiency; it is about responsibility. By aligning our growth with respect for the environment, we contribute to a healthier planet while delivering medicines that improve lives worldwide.
